August 23, 2010 - The radiation therapy skin cancer business of Topex Inc. is being sold to Sensus Healthcare. Sensus will take over sales of the low-energy SRT 100 superficial radiotherapy treatment system.
Since TOPEX received U.S. Food and Drug Administration (FDA) clearance for the system in 2007, many systems have been operating worldwide at hospital radiation oncology centers and in dermatology and veterinary oncology practices for the treatment of skin cancer.
The low-energy superficial radiotherapy system provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, especially primary lesions requiring difficult or extensive surgery with sensitive structures in the head and neck regions, such as the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear, that would otherwise lead to a less-than-desirable cosmetic outcome. This treatment procedure does not require the use of anesthetics and eliminates the need for skin grafting.
The incidence of skin cancer has steadily increased over the past 75 years. During the 1930s, one in 1,500 developed skin cancer. In 1960, the rate had risen to one in 600 and in 2000, the rate increased to one in 66. The National Cancer Institute estimates that one out of five is now at risk for developing some form of skin cancer during their lifetime.
Increased exposure to the sun without skin protection and a decreasing natural ozone layer are cited as the chief causes of this increase. It is estimated that up to 1.3 million new skin cancer cases are diagnosed annually in the United States and more than 2.5 million worldwide. This is projected to increase at a rate of four percent each year.
For more information: www.sensushealthcare.com